

Clonidogrel as prophylactic treatment for migraine

Submission date 21/03/2008	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
Registration date 21/04/2008	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 17/11/2014	Condition category Nervous System Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr John Chambers

Contact details
Cardiothoracic Centre
St Thomas Hospital
Westminster Bridge Road
London
United Kingdom
SE1 7EH

Additional identifiers

Protocol serial number
Version 05

Study information

Scientific Title

Study objectives

That clopidogrel is effective for the prophylaxis of migraine with or without the presence of a patent foramen ovale.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from Guy's Hospital Ethics Committee on the 17th December 2007 (ref: 07/H0804/139).

Study design

Randomised placebo-controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Migraine

Interventions

1. Clopidogrel 75 mg orally once daily to be taken for three months
2. Placebo

The study has a one month run-in prior to treatment. After the three month treatment there is no further follow-up.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Clopidogrel

Primary outcome(s)

The number of headache-free days in one month (28 days). Migraine will be assessed using a headache diary kept for 28 days during run-in then again for the final 28 days of the three-month treatment period.

Key secondary outcome(s)

1. Frequency of attacks
2. Severity of attacks
3. Duration of attacks

Migraine will be assessed using a headache diary kept for 28 days during run-in then again for the final 28 days of the three-month treatment period. In addition the patients will have the 6-

item Headache Impact Test (HIT-6) and Migraine Disability Assessment (MIDAS) questionnaires at the start and end of the study.

Completion date

30/04/2011

Eligibility

Key inclusion criteria

1. Age greater than 18 years, either sex
2. Migraine as defined by International Headache Criteria
3. More than two attacks in 28 days

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. High risk features suggesting cerebral malignancy
2. Contra-indications to clopidogrel
3. Requirements for routine non-steroidal anti-inflammatory agent or aspirin other than for acute headache
4. Use of an investigational product within three months
5. Inability to understand English
6. Pregnancy or breast-feeding
7. Abnormal platelet or liver function

Date of first enrolment

01/05/2008

Date of final enrolment

30/04/2011

Locations

Countries of recruitment

United Kingdom

England

Study participating centre
Cardiothoracic Centre
London
United Kingdom
SE1 7EH

Sponsor information

Organisation
Guy's and St Thomas NHS Trust (UK)

ROR
<https://ror.org/00j161312>

Funder(s)

Funder type
Charity

Funder Name
The Dunhill Medical Trust (UK)

Funder Name
Sanofi-Aventis (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/12/2014		Yes	No
HRA research summary			28/06/2023	No	No

